Saturday - June 7, 2025
BREZTRI Met Primary Endpoints in KALOS and LOGOS Phase III Trials in Asthma
May 03, 2025
WILMINGTON, Delaware, May 3 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma

Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca's fixed-dose triple-combination therapy BREZTRI AEROSPHERE (budesonide/glycopyrronium/formoterol fumarate or BGF (320/28.8/9.6ug)) met . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products